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Available online 15 June 2017Altered concentrations of monoamine neurotransmitters and metabolites have been repeatedly found in people
with Down syndrome (DS, trisomy 21). Because of the limited availability of human post-mortem tissue, DS
mouse models are of great interest to study these changes and the underlying neurobiological mechanisms. Al-
though previous studies have shown the potential of Ts65Dn mice – the most widely used mouse model of DS –
tomodel noradrenergic changes, a comprehensivemonoaminergic characterization inmultiple brain regions has
not been performed so far. Here, we used RP-HPLC with electrochemical detection to quantify (nor)adrenergic
(NA, adrenaline and MHPG), dopaminergic (DA, HVA and DOPAC), and serotonergic compounds (tryptophan,
5-HT and 5-HIAA) in ten regionally dissected brain regions of Ts65Dn mice, as well as in Dp1Tyb mice – a
novel DS mouse model. Comparing young adult aneuploid mice (2.5–5.5 months) with their euploid WT litter-
mates did not reveal generalized monoaminergic dysregulation, indicating that the genetic overload in these
mice barely affected the absolute concentrations at this age. Moreover, we studied the effect of aging in
Ts65Dn mice: comparing aged animals (12–13 months) with their younger counterparts revealed a large num-
ber of signiﬁcant changes. In general, the (nor)adrenergic system appeared to be reduced, while serotonergic
compoundswere increasedwith aging. Dopaminergic alterationswere less consistent. These overall patterns ap-
peared to be relatively similar for Ts65Dn and WT mice, though more observed changes were regarded signiﬁ-
cant for WT mice. Similar human post-mortem studies are necessary to validate the monoaminergic construct
validity of the Ts65Dn and Dp1Typ mouse models.nd Alzheimer Res
ein 1, 9713 GZ Gr
ect.com).












Down syndrome (DS), caused by an additional copy of chromosome
21 (HSA21), is the most common intellectual disability with a genetic
origin affecting nearly six million people worldwide (Ballard et al.,
2016). DS is generally characterized by behavioral alterations (Dekker
et al., 2015b) and reduced cognitive capacities, in particular impaired
verbal short-term memory, explicit long-term memory, morphosyntax
and an average IQ of 45 (Lott and Dierssen, 2010; Vicari et al., 2004).earch Center,
oningen, The
ccess article underMoreover, people with DS are at an extremely high risk to develop
dementia: 68–80% develop Alzheimer's disease (AD) by the age of
65 years (Wiseman et al., 2015), compared to 11% in the general
(non-intellectually disabled) population of 65 years and older
(Alzheimer's Assocation, 2016).
Elucidating the underlying neurobiological mechanisms affecting
behavior and cognition in DSwould greatly contribute to understanding
the pathophysiology, as well as facilitate development of novel disease-
modifying strategies. Of particular interest in this population are mono-
amine neurotransmitters: noradrenaline (NA), adrenaline, dopamine
(DA) and serotonin (5-HT) and their metabolites (summarized in
Fig. 1). A series of neurochemical studies has shown signiﬁcant alter-
ations in one or more monoamines in various brain regions (Godridge
et al., 1987; Reynolds and Godridge, 1985; Risser et al., 1997; Whittle
et al., 2007; Yates et al., 1981), cerebrospinal ﬂuid (CSF) (Kay et al.,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Schematic biosynthesis routes of monoamine neurotransmitters and their main metabolites. 5-HT is derived from the amino acid tryptophan, whereas DA (and thus NA and
adrenaline) are derived from the amino acid tyrosine. The molecular structures are provided for the compounds that are quantiﬁed in this study through reversed-phase high-
performance liquid chromatography (RP-HPLC) analyses. Abbreviations: AADC, aromatic amino acid decarboxylase; ALDH, aldehyde dehydrogenase; COMT, catechol-O-
methyltransferase; DBH, dopamine β-hydroxylase; DDC, DOPA decarboxylase; L-DOPA, L-3,4-dihydroxyphenylalanine (levodopa); MAO, monoamine oxidase; PNMT,
phenylethanolamine N-methyltransferase; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase.
236 A.D. Dekker et al. / Neurobiology of Disease 105 (2017) 235–2441987; Schapiro et al., 1987) and serum/plasma (Coppus et al., 2007;
Dekker et al., 2015a) of DS individuals as compared to non-DS controls.
Although monoaminergic alterations in CSF and serum/plasma like-
ly reﬂect changes in the brain, direct analysis of brain tissue is warrant-
ed to understand central neurotransmission alterations. Indeed, we
previously studied monoamines and metabolites in post-mortem
brain regions of behaviorally characterized patients in the general pop-
ulation with (early-onset) AD (Vermeiren et al., 2014a, 2014b, 2015,
2016), frontotemporal dementia (Vermeiren et al., 2016) and dementia
with Lewy bodies (Vermeiren et al., 2015). Surprisingly, despite the
high risk for dementia in DS, only a few post-mortem studies dating
back to the 1980s have investigated monoamines in DS. Unfortunately,
post-mortem brain samples from clinically and pathologicallywell-doc-
umented DS individuals have been rarely included in biobanks around
the world, severely limiting the possibilities for such research.
Thus, valid mousemodels of DS are of great interest to study the po-
tential monoaminergic alterations related to trisomy 21. In addition to
the differences between DS and non-DS controls, monoaminergic
changes have been reported in DS mouse models, in particular norad-
renergic alterations (Dierssen et al., 1997; Lockrow et al., 2011; Salehi
et al., 2009). These ﬁndings have been primarily observed in
Ts(1716)65Dn mice (Ts65Dn in short), the most widely used and best
characterized DS model. HSA21 contains 233 protein-encoding genes:
among those genes with a homologue in mice, the majority (~58%) is
found on a large segment of mouse chromosome 16 (Mmu16), and to
a lesser extent on shorter segments of Mmu10 and Mmu17 (Lana-
Elola et al., 2016). Ts65Dn mice carry an additional mini-chromosome
that is formed by the translocation of a duplicated segment of Mmu16to a small part of Mmu17 (Davisson et al., 1990), making them trisomic
for approximately 50% of the genes homologous to HSA21, but also for
60 non-homologous genes on Mmu17 (Duchon et al., 2011).
Of profound interest is the signiﬁcant loss of neurons in the locus
coeruleus (LC), the key production site of NA in the pons, in Ts65Dn
mice of 12 months of age but not in Ts65Dn mice at 4 months of age
as compared to age-matched euploid wildtype (WTTs65Dn) littermates
(Fortress et al., 2015; Lockrow et al., 2011). Neurodegeneration with
progressive aging was further demonstrated by the signiﬁcant loss of
axonal processes and shrinkage of the noradrenergic neurons between
4 and 12 months in Ts65Dn, but not in WTTs65Dn (Lockrow et al.,
2011). Similarly, Salehi and colleagues found a reduced number of LC
neurons in Ts65Dn mice at 6 months and 18 months of age, but not in
those of 3 months of age, as compared to age-matched WTTs65Dn mice.
Moreover, NA levels in the hippocampus were signiﬁcantly lower in
Ts65Dn than in WTTs65Dn at 18 months. Despite the pronounced LC de-
generation, impaired NA-modulated contextual learning could be res-
cued in these mice after treatment with the noradrenergic prodrug L-
threo-3,4-dihydroxyphenylserine (L-DOPS) or the β1-adrenergic recep-
tor partial agonist xamoterol (Salehi et al., 2009). Restoration of im-
paired noradrenergic neurotransmission may thus serve as potential
disease-modifying therapy in DS (Phillips et al., 2016).
Despite a large number of studies using Ts65Dnmice, a comprehen-
sive monoaminergic characterization of the brain of this mouse model
has not been conducted so far. Therefore, this study aimed to investigate
the potential of DS mouse models (construct validity) in modelling the
monoaminergic changes in DS by (1) establishing the monoaminergic
proﬁle in ten regionally dissected brain regions of aneuploid Ts65Dn
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studying the effect of aging in Ts65Dn and WTTs65Dn mice. Using an
optimized reversed-phase high-performance liquid chromatography
(RP-HPLC) set-up with electrochemical detection we detected and
quantiﬁed (nor)adrenaline and the metabolite 3-methoxy-4-
hydroxyphenylglycol (MHPG), DA with its metabolites homovanillic
acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC), tryptophan,
and 5-HT with its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in
each of these brain regions.
Whereas Ts65Dnmice have proven very useful for studying various
phenotypic features present in peoplewith DS (Gardiner, 2015), the ad-
ditional 60 genes fromMmu17 that are not homologous to HSA21 may
complicate the interpretation of generated data (Duchon et al., 2011).
Therefore, newmouse models have been developed that are only triso-
mic for genes homologous to HSA21, such as the Dp(16)1Yey strain that
is trisomic for the entire homologous segment on Mmu16 (Yu et al.,
2010). Similar to Dp(16)1Yey, the Dp1Tyb mouse model has been gen-
erated to exclude the effect of the irrelevantMmu17 genes triplicated in
Ts65Dn. Using Cre/loxP-mediated recombination, Dp1Tyb mice were
engineered with a triplication of Mmu16 genes from Lipi to Zbtb21 in-
cluding 148 protein-encoding Mmu16 genes (Lana-Elola et al., 2016).
Given the debate on the non-homologous genes in Ts65Dn mice, we
also performed a ﬁrst exploratory analysis of themonoaminergic proﬁle
of this new Dp1Typ mouse model.
2. Materials & methods
2.1. Animals
As Ts65Dn is the most widely used DS mouse model, the aim of this
project was to establish its monoaminergic proﬁle and evaluate the ef-
fect of aging in this model. Since Ts65Dn are trisomic for 60 Mmu17
genes that are not homologous to HSA21, we also conducted a ﬁrst
(pilot) study with young Dp1Tyb mice, which resemble the human sit-
uation more closely from a genetic point of view. Given the time-inten-
sive nature of this project, the availability of aged Ts65Dnmice and that
the aforementioned studies in Ts65Dn implicated monoaminergic
changes with aging, possibly resembling the changes in humans, we
studied the effect of aging only in the Ts65Dn mouse model.
2.1.1. Ts65Dn mice
Male Ts65Dn (n = 32) and euploid WTTs65Dn littermates (n = 28)
were bred, aged and sacriﬁced in the Institut du Cerveau et de la Moelle
Epinière (ICM, Paris, France). To study the effect of aging, we considered
two age ranges (Table 1): young adult animals (~3–5.5 months) and
aged animals (~12–13 months). Since the original homozygous
Ts65Dnmice suffer from blindness due to the recessive retinal degener-
ation 1 mutation Pde6brd1, we used an alternative strain that is wild-
type for Pde6brd1 (The Jackson Laboratory, Bar Harbor, USA, stock num-
ber 005252), thus preventing retinal degeneration. The Ts65Dn colony
was maintained by crossing trisomic Ts65Dn females (B6EiC3Sn.BLiA-
Ts(1716)65Dn/DnJ) to B6EiC3Sn.Bli males (The Jackson Laboratory,
stock numbers 005252 and 003647, respectively). Mixed-genotype
groups were housed under standard conditions with ad libitum food
and water, constant room temperature and a 12 h light/dark cycle.Table 1
Overview of experimental groups.
Experimental groups Number of mice Age in days
Ts65Dn-young 21 117 (91–174)
WTTs65Dn-young 18 118.5 (110–174)
Ts65Dn-aged 11 377 (354–399)
WTTs65Dn-aged 10 382 (376–382)
Dp1Tyb 9 82 (79–93)
WTDp1Tyb 9 84 (79–93)
Age in days is provided as median with the age range between brackets.The experiments were compliant with the ethical standards and animal
welfare regulations of the FrenchMinistry of Agriculture and the EU Di-
rective 2010/63/EU. MC Potier has the authorization for experiments on
vertebrates (N°A-75-2138, Direction Départementale de la Protection
des Populations de Paris, Service Protection et Santé Animales,
Environnement).
2.1.2. Dp1Tyb mice
The engineering of the C57BL/6J.129P2-Dp(16Lipi-Zbtb21)1Tyb
Emcf/Nimr (Dp1Tyb) strain is described in Lana-Elola et al. (2016). In
this ﬁrst exploratory analysis of this model, we used young male
Dp1Tyb (n = 9) mice and euploid WTDp1Tyb littermates (n = 9) aged
2.5–3months (Table 1). All mice had been backcrossed at least 5 gener-
ations onto the C57BL/6J background. The animals were bred, aged and
sacriﬁced in the Francis Crick Institute (London, UK). Animals were
housed in speciﬁc pathogen free conditions, with ad libitum food and
water, constant room temperature and a 12 h light/dark cycle. The char-
acterization and breeding of Dp1Tyb mice was carried out under a Pro-
ject License granted by the UK Home Ofﬁce, and in accordance with the
EU Directive 2010/63/EU.
2.2. Sacriﬁce
After intraperitoneal anesthesia with pentobarbital, mice were
sacriﬁced by cervical dislocation and subsequently fully submersed in
liquid nitrogen (3 min) to stop metabolization of monoamines. Mice
were stored at−80 °C and shipped on dry ice to the Laboratory of Neu-
rochemistry and Behaviour in Antwerp for further processing.
2.3. Regional brain dissection
Brains were extracted from the frozen mice using surgical tools, and
subsequently micro-dissected on a cold plate under a binocular micro-
scope, resembling a previously published protocol (Van Dam et al.,
2005). Permouse, ten (sub)cortical brain regionswere obtained: frontal
cortex, temporal cortex, parietal cortex, occipital cortex, hippocampus,
striatum, (hypo)thalamus, brainstem, cerebellum and olfactory bulb.
The weight of the brain samples was determined in pre-weighted
Eppendorf tubes. Samples were kept at−80 °C until RP-HPLC analyses.
2.4. Sample preparation
Brain samples were defrosted to 4 °C and subsequently homoge-
nized in 800 μl sample buffer (50 mM citric acid, 50 mM phosphoric
acid, 0.1 mM EDTA, 8 mM KCl and 1.8 mM octane-1-sulfonic acid sodi-
um salt (OSA), adjusted to pH = 3.6) using a Bio-Gen PRO200 homog-
enizer (PRO Scientiﬁc Inc., Oxford, CT, USA). Thereupon, 450 μl
homogenatewas transferred onto a 3000 Da Amicon®Ultra 0.5 Centrif-
ugal Filter (Millipore, Ireland) that had been pre-washed (2×) using
450 μl sample buffer (centrifugation: 14,000 ×g, 25 min, 4 °C). The
Amicon® ﬁlter loaded with homogenate was centrifuged (14,000 ×g,
40 min, 4 °C). Per region per mouse, 5 μl of the resulting ﬁltrate was si-
multaneously injected by an Alexys™ AS 100 automatic sample injector
onto two parallel ALF-125 columns.
2.5. RP-HPLC
Noradrenergic (NA, adrenaline and MHPG), dopaminergic (DA,
DOPAC and HVA) and serotonergic compounds (TRP, 5-HT and 5-
HIAA) were simultaneously quantiﬁed in one run using an optimized
RP-HPLC set-up with ion-pairing (OSA) and amperometric electro-
chemical detection, as published before (Dekker et al., 2015a; Van
Dam et al., 2014). In summary, we used an Alexys™ Dual Monoamines
Analyzer (Antec Leyden BV, Zoeterwoude, The Netherlands), including
two LC 110 pumps for a constant ﬂow rate (40 μl/min), two parallel
microbore ALF-125 columns (250 mm × 1 mm, 3 μm particle size, 36
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pounds and two Decade II electrochemical amperometric detectors
with VT03 electrochemical ﬂow cells containing an In Situ Ag/AgCl ref-
erence electrode (ISAAC) at 670 mV and a 0.7 mm glassy carbon work-
ing electrode. RP-HPLC runs were conducted per brain region and
compounds were analyzed in duplicate (output ranges resp. 1 nA and
500 pA). The mobile phase consisted of the aforementioned sample
buffer with 13% methanol as organic modiﬁer. Dihydroxybenzylamine
hydrochloride (DHBA) and 5-hydroxy-N-methyl tryptamine oxalate
(5-HMT) were used as internal standards. Chromatograph analyses
were performed with Clarity™ software (DataApex Ltd., Prague, Czech
Republic).
2.6. Statistics
Histograms and Shapiro-Wilk tests (P b 0.05) demonstrated that the
monoamines and metabolites did not have a normal distribution over-
all. Accordingly, non-parametric tests were selected: Mann Whitney U
tests were used to compare all monoaminergic data between Dp1Tyb
and WTDp1Tyb littermates, whereas Kruskal-Wallis with post-hoc
Mann Whitney U tests were applied to compare the young Ts65Dn,
young WTTs65Dn, aged Ts65Dn and aged WTTs65Dn groups. To account
for multiple comparisons we corrected the P-values using the
Benjamini-Hochberg procedure with a False Discovery Rate of 0.05
given the exploratory and hypothesis-generating nature of this study.
Only the corrected P-values smaller than 0.05 (i.e. regarded signiﬁcant)
are reported in Tables 2–4. Statistical analyses were performed using
IBM SPSS Statistics version 23.0 and Microsoft Ofﬁce Excel 2010.
3. Results
Each monoaminergic compound was detected and quantiﬁed in all
ten brain regions. Based on these concentrations, ﬁve accompanying ra-
tios were calculated: MHPG/NA (reﬂecting noradrenergic metabolism),
DOPAC/DA and HVA/DA (reﬂecting dopaminergic catabolism), 5-HIAA/
5-HT (reﬂecting serotonergic catabolism) and, ﬁnally, HVA/5-HIAA
(indicating the effect of serotonergic inhibition on dopaminergic neuro-
transmission). In the supplementary material (S1-S6), the concentra-
tions and ratios for each brain region are provided per experimental
group (median and quartiles, including the number of samples in
which a speciﬁc compound was detected). All compounds and ratios
were compared between young Ts65Dn vs. young WTTs65Dn (Table 2),
aged Ts65Dn vs. aged WTTs65Dn (Table 3), aged Ts65Dn vs. young
Ts65Dn (Table 4), aged WTTs65Dn vs. young WTTs65Dn (Table 5), and
young Dp1Tyb vs. young WTDp1Tyb mice. Since the Ts65Dn and
Dp1Tyb mouse models have different genetic backgrounds and were
bred and housed in two different institutes, these DS models are not
compared with each other, but only to their age-matched WTTable 2






Frontal cortex – – – – – –
Temporal cortex – – – – – –
Parietal cortex – – – – – –
Occipital cortex – – – – – –
Hippocampus – – – – –
Striatum – – – – – –
(Hypo)thalamus – – – –
Brainstem – – – – – –
Cerebellum – – – – – –





Red boxes indicate a signiﬁcant increase, and green boxes depict a signiﬁcant decrease for a com
consequent overall increase (red) or decrease (green). 5-HIAA, 5-hydroxyindoleacetic acid; 5-H
homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline.littermates (same background, same conditions). Signiﬁcant P-values
of the individual group comparisons are provided in Tables 2–4.
3.1. Effect of aneuploidy
3.1.1. Ts65Dn vs. WTTs65Dn mice
To determine the effect of the aneuploidy on themonoamine neuro-
transmitters and their metabolites, we compared Ts65Dn mice with
their WTTs65Dn littermates. First of all, we compared the young animals
(Table 2):MHPG and the accompanyingMHPG/NA ratio in the olfactory
bulb were signiﬁcantly higher in young Ts65Dn than in youngWTTs65Dn
mice. No other signiﬁcant changes in the (nor)adrenergic system were
found. Concerning the dopaminergic system, DA and DOPAC were sig-
niﬁcantly lower in the (hypo)thalamus of Ts65Dn compared to
WTTs65Dn mice, but not in other regions. With respect to the serotoner-
gic compounds, decreased levels were observed for 5-HIAA and 5-HT in
the hippocampus, and 5-HIAA in the occipital cortex of young Ts65Dn
compared to young WTTs65Dn mice.
Secondly, we compared the aged Ts65Dn mice with their aged
WTTs65Dn littermates (Table 3). Apart from a signiﬁcant reduction of
MHPG in the frontal cortex of Ts65Dnmice, no other signiﬁcant changes
were observed for the (nor)adrenergic system in any of the brain re-
gions. Although DA, DOPAC and HVA did not differ signiﬁcantly be-
tween the groups, the subsequent ratios turned out to be signiﬁcantly
altered: the DOPAC/DA ratio was lower in the frontal cortex, parietal
cortex, and cerebellum of Ts65Dn mice (indicating reduced DA catabo-
lism), while the ratio HVA/DA in the temporal cortex was increased
(indicating increased DA metabolization) in aged Ts65Dn compared to
aged WTTs65Dn mice. No differences were found in the serotonergic
system.
3.1.2. Young Dp1Tyb vs. young WTDp1Tyb mice
In addition to the Ts65Dnmousemodel, we also assessed themono-
aminergic proﬁle of young Dp1Tyb mice in comparison with their
WTDp1Tyb littermates: only the NA concentration in the occipital cortex
was signiﬁcantly increased in Dp1Tyb mice compared to WTDp1Tyb
(P=0.047), while none of the othermonoamines,metabolites or ratios
were signiﬁcantly altered between both groups.
3.2. Effect of aging
3.2.1. Aged Ts65Dn vs. young Ts65Dn mice
To study the effect of aging in Ts65Dn mice, we compared two age
groups: Table 4 depicts the signiﬁcant differences between aged
Ts65Dn (~12–13 months) and their younger counterparts (~3–
5.5months). To start with the noradrenergic system, NA concentrations
only differed in the striatum, but not in other regions. Adrenaline, in











– – – – – – – –
– – – – – – – –
– – – – – – – –
– – – – – – –
– – – – – –
– – – – – – – –
– – – – – – – –
– – – – – – – –
– – – – – – – –
0.006
0.024 0.024
– – – – – – – –
– – – – – –
pound or ratio in young Ts65Dn vs. youngWTTs65Dnmice. The summary row indicates the
T, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3-4-dihydroxyphenylacetic acid; HVA,
Table 3
Aged Ts65Dn vs. aged WTTs65Dn mice (aneuploidy effect).














Frontal cortex – – 0.023 – – – – 0.022 – – – – – –
Temporal cortex – n.d. – – – – – – 0.043 – – – –
Parietal cortex – – – – – – – 0.035 – – – – –
Occipital cortex – – – – – – – – – – – – – –
Hippocampus – – – – – – – – – – – – – –
Striatum – – – – – – – – – – – – – –
(Hypo)thalamus – – – – – – – – – – – – – –
Brainstem – – – – – – – – – – – – – –
Cerebellum – – – – – – – 0.034 – – – – – –
Olfactory bulb – – – – – – – – – – – – – –
Summary – – – – – – – – – – –
Red boxes indicate a signiﬁcant increase, and green boxes depict a signiﬁcant decrease for a compound or ratio in aged Ts65Dn vs. aged WTTs65Dn mice. The summary row indicates the
consequent overall increase (red) or decrease (green). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3-4-dihydroxyphenylacetic acid; HVA,
homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.d., not detectable.
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po)thalamus, and higher levels in the temporal cortex. Similarly, MHPG
was reduced in the frontal and parietal cortex, but was elevated in the
olfactory bulb. Consequently, the ratio MHPG/NA in the parietal cortex
and the striatum was decreased in aged compared to young Ts65Dn
mice. Overall, adrenaline, MHPG and theMHPG/NA ratio were predom-
inantly reduced with aging.
In contrast to these results, the changes in the dopaminergic system
are less consistent: DA was increased in the temporal cortex, but de-
creased in the striatum of aged vs. young Ts65Dnmice. DOPAC was sig-
niﬁcantly higher in the temporal cortex and cerebellum, while lower
HVA concentrations were found in the hippocampus and striatum.
The resultingDOPAC/DA andHVA/DA ratioswere not altered for the dif-
ferent brain regions, apart from an increased DOPAC/DA ratio in the cer-
ebellum and a decreased HVA/DA ratio in the temporal cortex.
Concerning the serotonergic system, 5-HIAA and the 5-HIAA/5-HT
ratio were increased in the temporal and parietal cortex, pointing at in-
creased serotonergic turnover. In the striatum, 5-HT was increased and
the ratio 5-HIAA/5HT reduced, indicating reduced serotonergic catabo-
lism. Finally, the inhibitory effect of the serotonergic system on the do-
paminergic system is reﬂected by the HVA/5-HIAA ratio, which turned
out to be signiﬁcantly lower in the striatum and the (hypo)thalamus
of aged Ts65Dn mice compared to their younger counterparts.
3.2.2. Aged WTTs65Dn vs. young WTTs65Dn mice
To evaluatewhether the observed changes in aged Ts65Dn vs. young
Ts65Dn mice are speciﬁc for this model, i.e. relate to the triplicated
genes or to aging in general, we also compared aged WTTs65Dn miceTable 4






Frontal cortex – 0.017 0.031 – – –
Temporal cortex – – – 0.012 0.035
Parietal cortex –
0.003
0.029 0.002 0.001 – –
Occipital cortex – – – – – –
Hippocampus – 0.039 – – – –
Striatum 0.004 – – 0.019 0.020 –
(Hypo)thalamus – 0.039 – – – –
Brainstem – – – – – –
Cerebellum – – – – – 0.000
Olfactory bulb – – 0.019 – – –
Summary
Red boxes indicate a signiﬁcant increase, and green boxes depict a signiﬁcant decrease for a co
consequent overall increase (red) or decrease (green). The yellow boxes indicate that the direct
direction of change is ex aequo (e.g. ↓↑) or inclines towards an increase (e.g. ↓↑↑) or decrease (e.
DOPAC, 3-4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydrox(~12–13 months) vs. young (~3–5.5 months) animals (Table 5). In the
(nor)adrenergic system, striatal NA concentrations were higher in
aged than in young WTTs65Dn mice, resembling the observed increase
in the striatum of Ts65Dn mice. Furthermore, adrenaline was lower in
the frontal cortex, parietal cortex, occipital cortex and (hypo)thalamus
of aged WTTs65Dn mice than in their younger counterparts, which
again (largely) resembles the aforementioned ﬁndings in the Ts65Dn
model. In the aged animals, MHPG levels were signiﬁcantly reduced in
cortical regions (parietal and occipital cortex), but increased in
brainstem and olfactory bulb. Accordingly, the ratio MHPG/NA de-
creased in parietal and occipital cortex, aswell as in the striatum, and in-
creased in the temporal cortex, brainstem and olfactory bulb.
In accordance with the Ts65Dn results, DA levels were signiﬁcantly
higher in the temporal cortex and lower in the striatum of aged vs.
youngWTTs65Dn mice. DOPAC and HVAwere both decreased in the stri-
atum as well. In addition, aged WTTs65Dn animals showed increased
DOPAC levels in the cerebellum and olfactory bulb, and reduced HVA
concentrations in the occipital cortex and (hypo)thalamus, compared
to their younger counterparts. Concerning the ratios, DOPAC/DA was
predominantly increased (parietal cortex, cerebellum and olfactory
bulb, but decreased in temporal cortex), while the ratio HVA/DA was
mainly decreased (temporal cortex, occipital cortex and hippocampus,
but increased in cerebellum).
Finally, an overall increase of serotonergic compounds became ap-
parent when comparing aged vs. young WTTs65Dn mice. Signiﬁcant in-
creases were found for tryptophan in the temporal cortex and
olfactory bulb, 5-HT in the striatum, 5-HIAA in the frontal cortex, tem-











– – – – – – – –
– – 0.005 – – 0.000 0.003 –
– – – – – 0.004 0.047 –
– – – – – – – –
0.043 – – – – – – –
0.001 – – – 0.005 – 0.015 0.007
– – – – – – – 0.012
– – – – – – – –
– 0.000 – – – – – –
– – – – – – – –
mpound or ratio in aged Ts65Dn vs. young Ts65Dn mice. The summary row indicates the
ion of the change differed between the different regions: the arrows illustrate whether the
g. ↓↓↑). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine;
yphenylglycol; NA, noradrenaline.
Table 5
Aged WTTs65Dn vs. young WTTs65Dn mice (aging effect).














Frontal cortex - 0.000 - - - - - - - - - 0.009 0.000 -
Temporal cortex - n.d. - 0.013 0.030 - - 0.013 0.000 0.000 - 0.000 - 0.000
Parietal cortex - 0.000 0.000 0.000 - - - 0.011 - - - - 0.008 -
Occipital cortex - 0.000 0.001 0.000 - - 0.010 - 0.001 - - - - 0.010
Hippocampus - - - - - - - - 0.030 - - - - -
Striatum 0.014 - - 0.007 0.004 0.045 0.003 - - - 0.001 - 0.002 0.005
(Hypo)thalamus - ↓ 0.001 - - - - 0.002 - - - - - - 0.000
Brainstem - - 0.007 0.001 - - - - - - - - - -
Cerebellum - - - - - 0.000 - 0.000 0.017 - - 0.001 - -
Olfactory bulb - - 0.000 0.000 - 0.047 - 0.012 - 0.000 - - - -
Summary
Red boxes indicate a signiﬁcant increase, and green boxes depict a signiﬁcant decrease for a compound or ratio in agedWTTs65Dn vs. youngWTTs65Dnmice. The summary row indicates the
consequent overall increase (red) or decrease (green). The yellow boxes indicate that the direction of the change differed between the different regions: the arrows illustrate whether the
direction of change is ex aequo (e.g. ↓↑) or inclines towards an increase (e.g. ↓↑↑) or decrease (e.g. ↓↓↑). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine;
DOPAC, 3-4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.d., not detectable.
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creased in the striatum. As in Ts65Dn mice, the ratio HVA/5-HIAA was
generally reduced in aged WTTs65Dn mice, indicating enhanced seroto-
nergic inhibition on the dopaminergic system.
4. Discussion
Using a previously optimized and validated RP-HPLC methodology
(Van Dam et al., 2014), we detected noradrenergic (NA, adrenaline
and MHPG), dopaminergic (DA, DOPAC and HVA) and serotonergic
(TRP, 5-HT and 5-HIAA) compounds in ten regionally dissected brain re-
gions to establish the monoaminergic proﬁles of Dp1Tyb and Ts65Dn
mice and theirWT littermates. First of all, we studied the effect of aneu-
ploidy in both models. Comparing young Dp1Tyb with youngWTDp1Tyb
showed that only occipital NA levels differed signiﬁcantly, suggesting
that the additional genes in Dp1Tyb mice hardly affected monoamine
concentrations at this age. Similarly, Tables 2 and 3 depict the compar-
isons between Ts65Dnmice andWTTs65Dn littermates, and do not show
generalized monoaminergic dysregulation either, even though a few
more changes were regarded signiﬁcant than in the Dp1Tyb mouse
model. Accordingly, the genetic overload in these DS mouse models
barely affected the absolute monoaminergic concentrations at the ana-
lyzed ages. Secondly, we studied the effect of aging within Ts65Dn and
WTTs65Dn mice comparing aged (~12–13 months) vs. young animals
(~3–5.5months). The overall patterns ofmonoaminergic alterations ap-
peared to be relatively similar in both genotypes, thoughmore observed
changes (especially in the ratios)were regarded signiﬁcant forWTTs65Dn
mice. Indeed, these overall patterns, rather than the individual concen-
tration changes in a speciﬁc region, aremost relevant in this exploratory
study. In the next section, the main patterns and changes will be
highlighted and discussed.
4.1. Noradrenergic system
The LC, located in the pons near the fourth ventricle, is the major
source of NA in the brain. The ascending noradrenergic neurons origi-
nating from this small nucleus project to an extensive number of (sub)-
cortical brain regions, including the frontal cortex, hippocampus,
striatum, (hypo)thalamus, cerebellum and olfactory bulb, mediating,
among others, arousal, attention and contextual memory. Importantly,
LC neurons are the sole source of NA for the cortex, hippocampus, cere-
bellum and most of the thalamus (Aston-Jones and Cohen, 2005; Trillo
et al., 2013; Vermeiren et al., 2016). A loss of LC neuronsmay thus espe-
cially affect these brain areas.
Previously, such a loss was reported in Ts65Dn mice of 6, 12 and
18 months but not in younger Ts65Dn mice (aged 3 and 4 months)compared to age-matched WTTs65Dn mice (Fortress et al., 2015;
Lockrow et al., 2011; Salehi et al., 2009). Here, we did not observe signif-
icant NA concentration changes between Ts65Dn and WTTs65Dn in both
age groups for the brainstem (including LC) or any of the noradrenergic
projection regions (Tables 2 and 3). Indeed, immunohistochemical
characterization of the catecholaminergic nuclei (anti-tyrosine hydrox-
ylase antibodies) previously showed intense staining of the LC in both
Ts65Dn and control mice (3 months) without evident differences be-
tween both groups, indicating that the additional genes in Ts65Dn did
not inﬂuence the early LC development (Megías et al., 1997). This is fur-
ther supported by human ﬁndings: NA levels were not signiﬁcantly al-
tered in the frontal cortex of fetal DS tissue (20 weeks) as compared
to age-matched non-DS fetuses (Whittle et al., 2007). Similarly, the ge-
netic overload in Dp1Tybmice does not appear to affect NA levels other
than an increase in the occipital cortex in comparison with WTDp1Tyb
mice – that is the only signiﬁcant difference in all compounds and re-
gions in this strain. Next, comparing trisomic mice with their WT litter-
mates revealed no signiﬁcant changes in adrenaline, whereas MHPG
was only altered in the olfactory bulb of young Ts65Dn vs. WTTs65Dn
and frontal cortex of aged Ts65Dn vs. WTTs65Dn mice. The latter resem-
bles the reduced levels of MHPG, which freely diffuses over the blood-
brain barrier, in serum of elderly DS individuals as compared to non-
DS controls (Dekker et al., 2015a), and may relate to the previously re-
ported deﬁcits in (pre)frontal cortex-mediated spatial workingmemory
in Ts65Dnmice aged 9–12months (Dudchenko, 2004; Faizi et al., 2011;
Yoon et al., 2008). Nevertheless, it appears that the aneuploidy had a
very limited effect on the (nor)adrenergic system.
In contrast, the effect of aging (i.e. comparing aged vs. young animals
of the same genotype) is pronounced for adrenaline andMHPG, but not
for NA. We did not ﬁnd age-related NA alterations other than the in-
creasedNA levels in the striatum(Tables 4 and 5). Interestingly, the pre-
cursor of NA, that is DA, was decreased in the striatum of the agedmice,
possibly pointing at an increased turnover of DA into NA (Tables 4 and
5). The virtually unaltered NA levels between the young and aged ani-
mals possibly relate to enhanced NA synthesis in the remaining norad-
renergic cells, i.e. a compensatory mechanism (Schapiro et al., 1987).
With progressive neuronal loss in the LC during aging (Fortress et al.,
2015; Lockrow et al., 2011; Salehi et al., 2009), which is also observed
in DS (Mann et al., 1987b; Marcyniuk et al., 1988), the increasingly
smaller number of remaining cells will not be able to keep noradrener-
gic neurotransmission at level, causing NA concentrations to start de-
creasing from a certain moment onwards. Indeed, Salehi et al. found
an age-related decrease in hippocampal NA concentrations, which was
only signiﬁcant for Ts65Dn vs.WTTs65Dn at 18months. Interestingly, im-
munostaining for the β1-adrenergic receptor, present on postsynaptic
targets of LC neurons in the hippocampus, revealed an increased size
241A.D. Dekker et al. / Neurobiology of Disease 105 (2017) 235–244(at 3 and 6 months) and number (at 6 months) of immune-reactive
cells in Ts65Dn mice compared with age-matched WTTs65Dn mice,
pointing at a postsynaptic compensation for the age-related decrease
in NA levels (Salehi et al., 2009). This may resemble the human situa-
tion, where signiﬁcantly reduced NA levels have been reported later in
life in several (sub)cortical post-mortem brain samples of elderly DS in-
dividuals presenting AD neuropathology as compared to controls
(Godridge et al., 1987; Reynolds and Godridge, 1985; Risser et al.,
1997; Yates et al., 1981).
Conversely, adrenaline levels appear to be substantially altered over
time in both Ts65Dn andWTTs65Dnmice. A relatively similar patternwas
observed for both genotypes: older animals had signiﬁcantly decreased
adrenaline levels in cortical regions and (hypo)thalamus (Tables 4 and
5). Hippocampal adrenaline was also reduced in aged Ts65Dn. Adrena-
line is formed by methylation of NA by the rate-limiting enzyme
phenylethanolamine N-methyltransferase (PNMT, Fig.1). The reduced
adrenaline levels are not likely due to reduced NA levels, given the
fact that NA levels were unaltered. Instead, lower adrenaline levels
may be due to a decrease in the amount or activity of PNMT enzyme.
Burke and co-workers, for instance, described a strong reduction of en-
zymatic activity due to lower amounts of PNMT enzymes in human AD
brain tissue as compared to controls (Burke et al., 1987). Since the cur-
rent study methodology did not enable enzymatic measurements (the
small tissue samples were entirely used for RP-HPLC analyses), future
studies need to elucidate whether PNMT plays a role in the adrenergic
changes in these mice.
MHPG levels were also affected by aging: reduced adrenaline
levels in the frontal and parietal cortex of aged Ts65Dnmice, and pa-
rietal and occipital cortex of aged WTTs65Dn mice likely resulted in
the decreased MHPG levels in these regions. Whereas MHPG and
the MHPG/NA ratio generally decreased with aging in Ts65Dn, the
pattern for WTTs65Dn mice was more diffuse. NA and adrenaline are
converted into MHPG through the enzymes monoamine oxidase
(MAO, Fig.1) and catechol-O-methyltransferase (COMT, Fig.1).
Previously, MAO activity in platelets of DS individuals was found to
be reduced (Benson and Southgate, 1970; Fowler et al., 1981) or
unaltered (Lott et al., 1972), whereas COMT activity was higher
(Gustavson et al., 1973) or unaltered (Brahe et al., 1985) in DS eryth-
rocytes. The COMT enzyme is a methyl transferase, using the methyl
group of S-adenosylmethionine (SAM). The levels of the methyl
donor SAM are reduced in DS (Dekker et al., 2014), suggesting that
COMT activity might be reduced in DS as well. Nevertheless, it
remains to be elucidated whether the amount or activity of MAO
and COMT change over time in these mice.
Taken together, the (nor)adrenergic systemwas not substantially af-
fected by the aneuploidy in Ts65Dn or Dp1Tybmice. However, aging re-
vealed strong alterations in multiple brain regions. Since LC
degeneration and altered (nor)adrenergic neurotransmission are impli-
cated inDS andAD, others have studied the effect of (nor)adrenergic ag-
onists in (aged) Ts65Dn mice as potential therapeutic strategies
(Phillips et al., 2016). Faizi and colleagues, for instance, reported repro-
ducible learning andmemory deﬁcits in Ts65Dnmice of 9–12months of
age that could be restored by administering the β1-adrenergic receptor
partial agonist xamoterol, thus suggesting that such cognitive deﬁcits
are (in part) mediated by the (nor)adrenergic system (Faizi et al.,
2011). Similarly, xamoterol and the NA-prodrug L-DOPS reversed con-
textual learning impairment in 6-month-old Ts65Dn mice (Salehi et
al., 2009). Moreover, the long-acting β2-adrenergic receptor agonist
formoterol signiﬁcantly improved cognitive capacities, synaptic density
and complexity of the dendritic tree of new dentate granule cells in the
hippocampus of Ts65Dn mice (5–6 months) (Dang et al., 2014). More
recently, Fortress and colleagues demonstrated LC degeneration in 12-
month-old Ts65Dnmice, and found that selective stimulation of the re-
maining noradrenergic LC neurons using designer receptors exclusively
activated by designer drugs (DREADDs) restored memory function
(Fortress et al., 2015).In the context of the high risk for AD in DS, it is important to note
that the amyloid precursor protein (APP) gene located on HSA21 is
also triplicated in Ts65Dnmice, but that the APP cleavage product amy-
loid-beta (Aβ) does not accumulate into plaques in Ts65Dnmice like in
the human condition (Gardiner, 2015; Reeves et al., 1995). Consequent-
ly, Ts65Dn is primarily amodel of the developmental trisomy21-related
deﬁcits in DS and can be used to study the effect of APP overexpression,
but not Aβ accumulation, with aging. Interestingly, Salehi and col-
leagues found that the loss of LC neurons was eliminated by deleting
the third copy of the APP gene in Ts65Dnmice, thus indicating that trip-
licated APP plays an essential role in LC degeneration (Salehi et al.,
2009). Indeed, a comparable cell loss of approximately 60% was found
in post-mortem LC samples from elderly DS (57–59 years) and AD pa-
tients (61–82 years) in the general population compared to healthy
controls (60–76 years) (German et al., 1992). Importantly, in both AD
and older DS samples, neuronal loss mainly affected the neurons
projecting to the cortex, while the non-cortical projecting cells were
spared (German et al., 1992; Marcyniuk et al., 1988). Similarly, LC neu-
ronal loss in Ts65Dnmice at 12monthswasmainly restricted to the ros-
tral neurons projecting to the forebrain and hippocampus, while the
caudal regions were spared (Lockrow et al., 2011). That might explain
the discrepancy between our ﬁnding of decreased cortical MHPG levels
and the increased MHPG concentrations in the brainstem with aging.
Cautious interpretation of the results is warranted in relation to ﬁndings
in aged post-mortem DS samples: virtually all DS individuals have om-
nipresent AD-pathology (i.e. Aβ plaques and tau tangles) in their brain
from the age of 40 years onwards (Mann, 1988), complicating the com-
parison between ﬁndings in DS and Ts65Dn mice that do not model
human AD neuropathology in DS.
Interestingly, LC degeneration does not only affect noradrenergic
neurotransmission, but also impacts cholinergic signaling (Lockrow et
al., 2011). Basal forebrain cholinergic neurons innervate the amygdala,
hippocampus and neocortex and are strongly implicated in attention
and memory processes. A signiﬁcant loss of cholinergic cells has been
found in AD and DS (Casanova et al., 1985; Mann et al., 1985; Mufson
et al., 2003) and in Ts65Dn mice by 12 months of age (Cooper et al.,
2001). LC degeneration in Ts65Dn mice appears to precede the onset
of cholinergic degeneration (Phillips et al., 2016). Indeed, Lockrow and
colleagues demonstrated that neurotoxin-induced NA depletion result-
ed in accelerated cholinergic degeneration in Ts65Dn mice, but not in
WTTs65Dn mice. Learning and memory deﬁcits were aggravated in
Ts65Dnmice as well (Lockrow et al., 2011). In the current study, we re-
port an overall decrease of adrenaline, MHPG and the MHPG/NA ratio
with aging in Ts65Dn mice, which may possibly contribute to choliner-
gic pathology in this mouse model. Future studies should consider
studying monoaminergic alterations in relation to cholinergic deﬁcits.
In conclusion, the (nor)adrenergic system was mainly affected by
aging rather than by aneuploidy. Comparing aged vs. young animals re-
vealed altered patterns across multiple brain regions. In particular,
adrenaline and MHPG differed in most cortical regions as well as in a
few subcortical structures. In Ts65Dn an overall decrease of adrenaline,
MHPG and the MHPG/NA ratio became apparent with aging. In
WTTs65Dn mice, adrenaline decreased with aging as well, while the di-
rections of change for MHPG and MHPG/NA were less straightforward.4.2. Dopaminergic system
DA, derived from L-tyrosine (Fig. 1), is mainly produced by the
substantia nigra (SN) and ventral tegmental area (VTA) located in the
mesencephalon. The SN primarily projects to the striatum (hence re-
ferred to as the nigrostriatal pathway), whereas the VTA projects to
the limbic (mesolimbic pathway) and cortical areas (mesocortical path-
way). DA is involved in regulatingmotor activity, emotions, reward and
has been associatedwith cognition (Lanari et al., 2006; Nieoullon, 2002;
Trillo et al., 2013).
242 A.D. Dekker et al. / Neurobiology of Disease 105 (2017) 235–244Studying the effect of aneuploidy on the dopaminergic system
showed that the levels of DA, DOPAC and HVA are virtually unaltered,
apart from decreased DA and DOPAC levels in the (hypo)thalamus of
young Ts65Dn vs. WTTs65Dn mice. Indeed, immunohistochemical stain-
ing of the dopaminergic neurons (anti-tyrosine hydroxylase antibodies)
in the SN and VTA of 3-month-old Ts65Dn mice and WTTs65Dn mice re-
vealed similar reaction intensities in both genotypes. The unaltered
morphology and number of reactive cells between Ts65Dn and
WTTs65Dn led the authors to conclude that the triplicated genes in
Ts65Dn do not affect the development of dopaminergic nuclei (Megías
et al., 1997). In young Ts65Dn mice, we found reduced DA levels in
the (hypo)thalamus. In the human situation, levels of DA and theDA re-
ceptor 1-containing complexwere signiﬁcantly lower in the frontal cor-
tex of DS fetuses than in age-matched control fetuses (Keihan Falsaﬁ et
al., 2016;Whittle et al., 2007). Furthermore, the lack of signiﬁcant alter-
ations between the older Ts65Dn andWTTs65Dn mice resembles the lack
of signiﬁcant changes in multiple post-mortem brain samples of DS in-
dividuals vs. controls (Godridge et al., 1987).
In contrast to the relatively consistent age-related patterns of change
in the (nor)adrenergic (section 4.1) and serotonergic systems (section
4.3), the results for the dopaminergic system are less consistent over
the months for the different compounds/regions. In the human situa-
tion, Mann and colleagues reported neuronal loss in the VTA, but not
in the SN of aged DS (51–65 years) and AD patients (53–89 years)
(Mann et al., 1987a). Indeed, comparison of older and younger DS sam-
ples revealed no signiﬁcant cell loss or reduced nucleolar volume in the
SN over time (Mann et al., 1987b). In Ts65Dnmice of 3 months, neuro-
nal loss was absent (Megías et al., 1997), but whether this is true for
aged Ts65Dn mice remains unclear. With aging, this study showed
that DA increased in the temporal cortex, but decreased in the striatum
for aged vs. young Ts65Dn mice, as well as for aged vs. young WTTs65Dn
mice. In mice, striatal neurons receive input from both the SN and VTA
(Zeiss, 2005). The ﬁnding that DOPAC is increased in various regions,
while HVA is decreased may relate to changes in MAO or COMT activity
(Fig. 1). COMT transfers a methyl group of SAM to DOPAC (3-O-methyl-
ation) resulting in HVA (Meiser et al., 2013). As described before, the
levels of the methyl donor SAM are reduced in DS (Dekker et al.,
2014), possibly affecting DOPAC methylation and thus HVA levels.
In short, the dopaminergic system was barely affected by the tripli-
cated HSA21-homologous genes in Ts65Dn or Dp1Tyb mice compared
to their WT littermates. Aging resulted in altered DA, DOPAC and HVA
levels, but further studies are required to mechanistically demonstrate
the cause of these alterations.
4.3. Serotonergic system
The indolamine 5-HT, derived from L-tryptophan (Fig. 1), is pro-
duced in various cell groups in the medulla, pons and mesencephalon.
The majority of ascending serotonergic neurons arise from the dorsal
and median raphe nuclei. In particular, the dorsal raphe nuclei project
to the cortex and striatum,while themedian raphenuclei target the cor-
tex, hippocampus and hypothalamus (Trillo et al., 2013). The main role
of the serotonergic system is (behavioral) inhibition, and regulation of
mood and aggression, for instance (Lanctôt et al., 2001).
Here, we did not ﬁnd widespread serotonergic changes between
Ts65Dn and WTTs65Dn mice. This is in accordance with the conclusion
of Megías et al. that the development of the serotonergic system is not
evidently inﬂuenced by the triplicated genes in Ts65Dn mice. Indeed,
their immunohistochemical results demonstrated a similar distribution
of serotonin-immunoreactive cells (anti-serotonin antibodies) in the
medial and dorsal raphe nuclei of Ts65Dn and WTTs65Dn mice at
3 months of age (Megías et al., 1997). 5-HT has been implicated in the
impaired hippocampal neurogenesis and dendritic hypotrophy in
Ts65Dn mice. Ts65Dn mice, similar to DS individuals, have a smaller
hippocampus indeed. Prenatal and neonatal treatment with the selec-
tive serotonin reuptake inhibitor ﬂuoxetine was found to normalizehippocampal neurogenesis and restore dendritic architecture, hippo-
campal cellularity and memory functions, even 1.5–3 months after
treatment cessation (reviewed in: Stagni et al., 2015). Although we do
not see many serotonergic changes between both genotypes, we did
ﬁnd signiﬁcantly reduced 5-HT and 5-HIAA levels in the hippocampus
of young Ts65Dn compared to young WTTs65Dn mice.
Whether these ﬁndings reﬂect the human situation remains unclear
due to a lack of (post-mortem) studies in youngDS individuals. Reduced
5-HT and 5-HIAA levels have, indeed, been reported in post-mortemDS
hippocampus samples (Godridge et al., 1987; Reynolds and Godridge,
1985). Other studies conﬁrmed the pattern of lower 5-HT and 5-HIAA
concentrations in DS (Risser et al., 1997; Seidl et al., 1999; Whittle et
al., 2007; Yates et al., 1986). These human post-mortem studies were
mainly performed on samples of elderly DS individuals presenting AD
neuropathology. For instance, Yates et al. studied six DS brains over
50 years of agewith numerous plaques and tangles in the cortex and re-
ported signiﬁcantly decreased 5-HT levels in amygdala, caudate nucleus
(part of striatum) and cingulate cortex, but no such changewas found in
a 27-year-old DS casewithout AD pathology (Yates et al., 1986). Consid-
ering fetal samples, however, Whittle et al. found reduced 5-HT and 5-
HIAA in the frontal cortex of fetal DS tissue as compared to age-matched
control aborted fetuses (Whittle et al., 2007), suggesting that this reduc-
tion is not related to the AD pathology, but to the trisomy 21 itself. To
which extent the murine ﬁndings thus resemble the human situation
is questionable given the fact that Aβ does not accumulate into plaques
in these mice, and comparison of aged Ts65Dn with aged WTTs65Dn
did not yield signiﬁcant alterations in any serotonergic compound or
region.
Studying the effect of aging within each genotype revealed a more
pronounced pattern: an overall increase of serotonergic compounds
with aging. This is in remarkable contrast with the aforementioned re-
duced serotonergic levels in the elderly DS brain samples. Indeed, com-
parison of older DS brains (with AD pathology) with young DS brains
(without/minimal AD pathology) revealed a signiﬁcant decrease in the
number of cells and the nucleolar volume with aging (Mann et al.,
1987b). Neuronal loss has been reported in the dorsal tegmental nucle-
us of the raphe nuclei in six DS patients over 50 years, as well as in AD
patients in the general population (Mann et al., 1985). The activity of
the tryptophan hydroxylase enzyme (Fig. 1), key to 5-HT biosynthesis,
is reduced in AD as well (Trillo et al., 2013), but whether this is also
true for DS and Ts65Dn is unclear. The link between AD pathology and
5-HT levels is further supported by the ﬁnding that the increased levels
of APP-derived βCTF peptide could be normalized in adult Ts65Dnmice
through ﬂuoxetine treatment (Stagni et al., 2015). Therefore, the under-
lying mechanism of serotonergic increase with aging in these mice
should be studied more extensively.
4.4. Future implications
Cautious interpretation of the results is required, because the under-
lying causes for (the lack of) monoaminergic alterations remain to be
elucidated. The virtually unaltered NA levels and the likely presence of
a compensatory mechanism, for instance, illustrate the necessity to
study monoaminergic alterations over a longer period of time. There-
fore, we propose that future studies should evaluate mice in a larger
number of age groups, for instance at 3, 6, 9, 12, 15, 18 and 21 months.
Immunohistochemical staining of (nor)adrenergic, dopaminergic and
serotonergic neurons, and measurements of the amount and activity
of key enzymes like PNMT, MAO and COMT (Fig. 1) in mice of different
ages would be a valuable addition to understand the age-related chang-
es. Despite the fact that the age ranges of the young Ts65Dn andDp1Tyb
mice in the current study slightly overlapped, the young Ts65Dn mice
were, on average, a few weeks older than the Dp1Tyb mice. Although
it was not the aim to compare both models with each other (different
genetic backgrounds and different institutes), it could be considered a
limitation of this study. Comparative age-matched studies should
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bred and housed at the same location. Moreover, the novel Dp1Tyb
mouse model has not been fully characterized yet. Dp1Tyb mice
present congenital heart defects comparable to DS (Lana-Elola et
al., 2016). Brain morphology and behavioral deﬁcits have not been
reported so far, although brain development and cognitive deﬁcits
in Dp1Tyb mice are expected to resemble those reported in the
essentially similar Dp(16)1Yey mouse model (Goodliffe et al.,
2016; Yu et al., 2010). Future studies should speciﬁcally evaluate
the behavioral phenotype (DS-related deﬁcits) of Dp1Tyb mice in
young, adult and aged life.
Currently, it is complex to evaluate themonoaminergic construct va-
lidity of themousemodels in comparisonwith the human situation, be-
cause of the lack of comprehensive post-mortem brain studies in DS.
The few available monoaminergic studies were conducted twenty to
forty years ago and have various methodological limitations, including
(1) long post-mortem delays (PMD), (2) small sample sizes, and (3) ab-
sence of DS brains free of extensive AD pathology. First, long PMDs over
30 h, for instance, were not unusual (Godridge et al., 1987; Risser et al.,
1997). Indeed, PMD is a confounding factor since it may affect the (re-
gional) concentrations of speciﬁc monoamines and metabolites
(Kontur et al., 1994; Van Dam et al., 2014). Therefore, we have sub-
mersed the mice in liquid nitrogen within minutes to stop further
monoaminergic turnover. Secondly, (very) small sample sizes were
used, ranging from 2 to 8 individuals (Godridge et al., 1987; Reynolds
and Godridge, 1985; Risser et al., 1997; Yates et al., 1981), thus compli-
cating the generalizability of thehuman results. Thirdly,mainly olderDS
brainswith virtually omnipresent AD-like neuropathologywere studied
(Mann, 1988),making it rather complex to disentangle the effects of AD
pathology, normal aging, and trisomy 21. To establish whether the
monoaminergic phenotypes of DS mouse models reﬂect alterations in
the human situation, we should study post-mortem human brain sam-
ples in greater detail, and thus prioritize the collection of these samples
through, for instance, multicenter brain bank initiatives. In short, mono-
amine neurotransmitter systems have not been comprehensively stud-
ied in the human DS situation, illustrating the need to be careful with
drawing conclusions at this stage about the monoaminergic construct
validity of Ts65Dn and Dp1Tyb mouse models.
With respect to the high risk for AD in DS, the scientiﬁc community
is in great need of animal models that integrate DS and AD phenotypes,
i.e. a model for the neurodevelopmental deﬁcits in DS (such as Ts65Dn)
that also develops AD pathology and related neurodegeneration over
time. Clearly, overexpression of wild-type APP is not sufﬁcient for the
development of vast AD neuropathology in these mice (Wiseman et
al., 2015). Indeed, we studied the effect of triplicated genes, including
APP, as well as the effect of normal aging in these mice that model DS,
but not AD. Novel rodent models for AD in DS are being developed,
but these are not available yet. Such models would be of great value to
study monoaminergic changes due to ‘pathologic’ aging.5. Conclusion
To the best of our knowledge, this study is the ﬁrst to comprehen-
sively quantify monoamine neurotransmitters and metabolites in ten
regionally dissected brain regions in two DS mouse models in compari-
son with their WT littermates. Monoaminergic concentrations were
barely altered by the aneuploidy in young adult Ts65Dn and Dp1Tyb
mice compared with their WT littermates. Aging to 12–13 months,
however, revealed strong alterations in themonoaminergic compounds
in multiple brain regions in both Ts65Dn and WT mice. Future studies
should focus on replicating these age-related monoaminergic alter-
ations and elucidate the underlying causes. Post-mortem studies
with human DS brain samples are necessary to validate the mono-
aminergic construct validity of the Ts65Dn and Dp1Typ mouse
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